Open Access
Subscription Access
Open Access
Subscription Access
Comparative Study between ACE Inhibitors and ARB in Hypertensive Patients
Subscribe/Renew Journal
The antihypertensive effect of ACE (Angiotensin Converting Enzyme Inhibitors) and ARB (Angiotensin Receptor Blockers) were compared in 60 young and middle aged patients of Essential hypertension. 1. Patients received therapy for two months. 2. Two groups of patients were randomly assigned to ACE Inhibitors and ARB period of two months. 3. Both treatments significantly reduced lying and standing, systolic and diastolic blood pressure as compared to base line value. 4. Comparing the treatments between zero to one month in both groups, fall in blood pressure was highly significant in patients receiving ACE Inhibitors and ARB. 5. Blood pressure was better sustained and side-effects were less with ARB than with ACE Inhibitors.
Keywords
Hypertension, Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers.
Subscription
Login to verify subscription
User
Font Size
Information
- Chobanian AV, Bakris GL, Black HR, Cushman WC, "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report". JAMA, 2003: 289, 2560 72.
- Walker W, Edward C .Clinical Pharmacy and Therapeutics first edition, Churchill Livingstone., 1994 p 2341-7.
- Tenenbaum A, Grossman E, Shemesh J, et al. Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough. Am. J. Hypertension, 2000: 13,776-782.
- Lennart Hansson, Lars H Lindholm, Leo Niskanen, Jan Lanke, Thomas Hedner, Anders Niklason, Kimmo Luomanmoki, Bjorn Dahlof, Ulf de Faire, Claes Morlin, Bengt E Karlberg, P O Wester, Jan-Erik Bjorck, for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial Lancet February 20, 1999; 353: 611-16
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002: 288, 2981-97
- Julius S, Keldsen SE, Weber M, Brunner HR, Ekman S, Hanson L, Hua T, Laragh J, Mc Innes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004 Jun 19; 363(9426):2022-31.
- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003: 42:239-46.
- Lindholm LH, Ibsen H, Dhlof B, Devr ux RB, Beevers G, Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pederson O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23;359(9311):1004-10.
Abstract Views: 269
PDF Views: 0